Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EvolusEOLS -0.33%69 Debt-to-EBITDA is -10.98 as of Mar. 2026. GuruFocus rates EOLS with a GF Score™ of 69/100 and a GF Value™ of $13.75 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 692 Drug Manufacturers companies, Evolus ranks worse than 144508.53% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Evolus's Debt-to-EBITDA or its related term are showing as below:
EOLS'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -18.36 Med: -2.47 Max: -0.37
Current: -12.04
During the past 11 years, the highest Debt-to-EBITDA Ratio of Evolus was -0.37. The lowest was -18.36. And the median was -2.47.
EOLS's Debt-to-EBITDA is ranked worse than 100% of 692
companies
in the Drug Manufacturers industry
Industry Median: 1.68
vs EOLS: -12.04
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Evolus Debt-to-EBITDA Related Terms
Evolus Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Evolus's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EOLS vs EBS, ELTP, AKBA: Debt-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Evolus's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Evolus Debt-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Evolus's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Evolus's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Evolus (EOLS) has a Debt-to-EBITDA of -10.98 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Evolus. According to the industry distribution chart, Evolus ranks #999999 out of 692 companies in the Drug Manufacturers industry.
Is Evolus' Debt-to-EBITDA too high?
Evolus' current Debt-to-EBITDA is -10.98. Based on the distribution chart, Evolus ranks #999999 out of 692 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Evolus has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Evolus' Debt-to-EBITDA compare to EBS and ELTP?
According to the Drug Manufacturers industry distribution chart, Evolus ranks #999999 out of 692 companies for Debt-to-EBITDA. This places Evolus in the lower half of its industry. The industry median Debt-to-EBITDA is 1.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Drug Manufacturers company?
The median Debt-to-EBITDA among Drug Manufacturers companies is 1.68, based on 692 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Evolus. For the Drug Manufacturers industry, the median Debt-to-EBITDA is 1.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Evolus's current Debt-to-EBITDA is -10.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Evolus stock overvalued right now?
Based on GuruFocus' analysis, Evolus (EOLS) is currently considered Possible Value Trap. The stock's GF Value™ is $13.75, compared to a current price of $6.02 — trading 56.2% below its estimated fair value. The current Debt-to-EBITDA is -10.98. Evolus' overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Evolus (EOLS), the current Debt-to-EBITDA is -10.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Evolus (EOLS) Overvalued in 2026?
Based on GuruFocus' analysis, Evolus stock appears to be undervalued.
The current stock price of $6.02 is trading 56.2% below its estimated GF Value™ of $13.75.
GuruFocus considers Evolus to be Possible Value Trap.
Key valuation signals for EOLS:
Debt-to-EBITDA: -10.98
GF Value™: $13.75 vs. price of $6.02 (56.2% below fair value)
No single metric tells the full story. See the EOLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
69GF Score
Get the complete analysis for EOLS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
EOLS has been successfully added to your 
